Literature DB >> 12079512

Expression of vascular endothelial growth factor and E-cadherin in human ovarian cancer: association with ascites fluid accumulation and peritoneal dissemination in mouse ascites model.

Noriyuki Akutagawa1, Akira Nishikawa, Masahiro Iwasaki, Takashi Fujimoto, Mizue Teramoto, Yoshimitsu Kitajima, Toshiaki Endo, Masabumi Shibuya, Ryuichi Kudo.   

Abstract

Ascites formation and peritoneal dissemination are critical problems in patients with advanced ovarian cancer. Vascular endothelial growth factor (VEGF), also known as angiogenic growth factor, is a potent mediator of peritoneal fluid accumulation and angiogenesis of tumors. E-Cadherin is an adhesion molecule that is important for cell-to-cell interaction. To elucidate the molecular mechanism of ascites formation and peritoneal dissemination of ovarian cancer, we examined the expression of VEGF and E-cadherin in different ovarian cancer cell lines and utilized nude mice to compare the biological characteristics of ovarian cancer cells. Three human ovarian cancer cell lines (AMOC-2, HNOA and HTBOA) were used in this study. Expression of genes was analyzed by northern blotting and RT-PCR methods. AMOC-2 expressed E-cadherin, but not VEGF. HNOA expressed VEGF without E-cadherin expression. HTBOA expressed both VEGF and E-cadherin. Each human ovarian cancer model revealed a specific feature. The AMOC-2 mouse had a single large peritoneal tumor without ascites or remarkable peritoneal dissemination. HTBOA and HNOA mice had bloody ascites and marked peritoneal dissemination. Introduction of VEGF antisense into HTBOA cells could inhibit the ascites formation. It is suggested that VEGF is important for the ascites formation via the increased vascular permeability effect. The deregulation of E-cadherin expression might be involved in the peritoneal dissemination. These molecules are important for the formation of specific features of advanced ovarian cancer. Ovarian cancer cell lines that had different gene expression patterns produced nude mouse human ovarian cancer models with different characteristics.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12079512      PMCID: PMC5927051          DOI: 10.1111/j.1349-7006.2002.tb01302.x

Source DB:  PubMed          Journal:  Jpn J Cancer Res        ISSN: 0910-5050


  45 in total

1.  Genetic manipulation of E-cadherin expression by epithelial tumor cells reveals an invasion suppressor role.

Authors:  K Vleminckx; L Vakaet; M Mareel; W Fiers; F van Roy
Journal:  Cell       Date:  1991-07-12       Impact factor: 41.582

2.  E-cadherin expression in squamous cell carcinomas of head and neck: inverse correlation with tumor dedifferentiation and lymph node metastasis.

Authors:  J H Schipper; U H Frixen; J Behrens; A Unger; K Jahnke; W Birchmeier
Journal:  Cancer Res       Date:  1991-12-01       Impact factor: 12.701

Review 3.  Tumor invasion and metastases--role of the extracellular matrix: Rhoads Memorial Award lecture.

Authors:  L A Liotta
Journal:  Cancer Res       Date:  1986-01       Impact factor: 12.701

4.  Vascular permeability factor (vascular endothelial growth factor) gene is expressed differentially in normal tissues, macrophages, and tumors.

Authors:  B Berse; L F Brown; L Van de Water; H F Dvorak; D R Senger
Journal:  Mol Biol Cell       Date:  1992-02       Impact factor: 4.138

5.  Expression of angiogenesis-related genes and progression of human ovarian carcinomas in nude mice.

Authors:  J Yoneda; H Kuniyasu; M A Crispens; J E Price; C D Bucana; I J Fidler
Journal:  J Natl Cancer Inst       Date:  1998-03-18       Impact factor: 13.506

6.  Flt-1 but not KDR/Flk-1 tyrosine kinase is a receptor for placenta growth factor, which is related to vascular endothelial growth factor.

Authors:  A Sawano; T Takahashi; S Yamaguchi; M Aonuma; M Shibuya
Journal:  Cell Growth Differ       Date:  1996-02

7.  Pathogenesis of ascites tumor growth: vascular permeability factor, vascular hyperpermeability, and ascites fluid accumulation.

Authors:  J A Nagy; E M Masse; K T Herzberg; M S Meyers; K T Yeo; T K Yeo; T M Sioussat; H F Dvorak
Journal:  Cancer Res       Date:  1995-01-15       Impact factor: 12.701

8.  Significant expression of vascular endothelial growth factor/vascular permeability factor in mouse ascites tumors.

Authors:  J C Luo; S Yamaguchi; A Shinkai; K Shitara; M Shibuya
Journal:  Cancer Res       Date:  1998-06-15       Impact factor: 12.701

9.  Vascular permeability factor (vascular endothelial growth factor) in guinea pig and human tumor and inflammatory effusions.

Authors:  K T Yeo; H H Wang; J A Nagy; T M Sioussat; S R Ledbetter; A J Hoogewerf; Y Zhou; E M Masse; D R Senger; H F Dvorak
Journal:  Cancer Res       Date:  1993-06-15       Impact factor: 12.701

10.  In oesophageal squamous cell carcinoma vascular endothelial growth factor is associated with p53 mutation, advanced stage and poor prognosis.

Authors:  S Uchida; Y Shimada; G Watanabe; H Tanaka; I Shibagaki; T Miyahara; S Ishigami; M Imamura
Journal:  Br J Cancer       Date:  1998-05       Impact factor: 7.640

View more
  8 in total

1.  Pro-inflammatory macrophage polarization enhances the anti-cancer efficacy of self-assembled galactomannan nanoparticles entrapped with hydrazinocurcumin.

Authors:  Manisha Kumari; Mahaveer P Purohit; Richa Pahuja; Satyakam Patnaik; Yogeshwer Shukla; Pradeep Kumar; Kailash C Gupta
Journal:  Drug Deliv Transl Res       Date:  2019-12       Impact factor: 4.617

2.  Molecular blockade of VEGFR2 in human epithelial ovarian carcinoma cells.

Authors:  Sirin A I Adham; Ifat Sher; Brenda L Coomber
Journal:  Lab Invest       Date:  2010-03-01       Impact factor: 5.662

3.  Absence of host-secreted protein acidic and rich in cysteine (SPARC) augments peritoneal ovarian carcinomatosis.

Authors:  Neveen Said; Kouros Motamed
Journal:  Am J Pathol       Date:  2005-12       Impact factor: 4.307

4.  Cancer-derived VEGF plays no role in malignant ascites formation in the mouse.

Authors:  Bayasi Guleng; Keisuke Tateishi; Fumihiko Kanai; Amarsanaa Jazag; Miki Ohta; Yoshinari Asaoka; Hideaki Ijichi; Yasuo Tanaka; Jun Imamura; Tsuneo Ikenoue; Yasushi Fukushima; Keita Morikane; Makoto Miyagishi; Kazunari Taira; Takao Kawabe; Masao Omata
Journal:  World J Gastroenterol       Date:  2005-09-21       Impact factor: 5.742

5.  Intraperitoneal administration of cisplatin plus bevacizumab for the management of malignant ascites in ovarian epithelial cancer: results of a phase III clinical trial.

Authors:  Hui Zhao; Xiaosong Li; Dianjun Chen; Jianhua Cai; Yan Fu; Huanrong Kang; Jie Gao; Ke Gao; Nan Du
Journal:  Med Oncol       Date:  2015-01-22       Impact factor: 3.064

6.  Ascites predicts treatment benefit of bevacizumab in front-line therapy of advanced epithelial ovarian, fallopian tube and peritoneal cancers: an NRG Oncology/GOG study.

Authors:  James S Ferriss; James J Java; Michael A Bookman; Gini F Fleming; Bradley J Monk; Joan L Walker; Howard D Homesley; Jeffrey Fowler; Benjamin E Greer; Matthew P Boente; Robert A Burger
Journal:  Gynecol Oncol       Date:  2015-07-26       Impact factor: 5.482

7.  Effect of AURKA Gene Expression Knockdown on Angiogenesis and Tumorigenesis of Human Ovarian Cancer Cell Lines.

Authors:  Cong Wang; Qin Yan; Minmin Hu; Di Qin; Zhenqing Feng
Journal:  Target Oncol       Date:  2016-12       Impact factor: 4.493

8.  Differential roles of uPAR in peritoneal ovarian carcinomatosis.

Authors:  Nada N Al-Hassan; Ali Behzadian; Ruth Caldwell; Vessela S Ivanova; Viqar Syed; Kouros Motamed; Neveen A Said
Journal:  Neoplasia       Date:  2012-04       Impact factor: 5.715

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.